Pancreatic Cancer: The Long-Standing "Last Frontier" in Cancer Therapy

Pancreatic cancer is often referred to as the "last frontier" of cancer treatment. Because effective early detection remains challenging, the majority of patients are diagnosed at a locally advanced or metastatic stage, when surgical resection is no longer feasible, and treatment options are consequently limited. Over the past two decades, dozens of targeted therapies and immunotherapies have dramatically improved survival outcomes in cancers such as lung cancer, breast cancer, and melanoma. In pancreatic cancer, however, only a handful of new therapies have achieved meaningful improvements in patient survival.

In metastatic pancreatic cancer, treatment has evolved primarily around FOLFIRINOX and gemcitabine plus nab-paclitaxel (Abraxane®). More recently, nal-irinotecan (Onyvide®)-based therapy has been introduced, yet treatment options following disease progression remain extremely limited. As a result, pancreatic cancer continues to be regarded as one of the malignancies with the highest unmet medical need in oncology.

Against this backdrop, the RASolute 302 study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine (NEJM), has emerged as a potential turning point in the treatment of pancreatic cancer. The study evaluated Daraxonrasib (RMC-6236), a next-generation RAS inhibitor developed by Revolution Medicines.

Beyond KRAS G12: Targeting Activated RAS Itself

Pancreatic cancer is a prototypical KRAS-dependent malignancy, with approximately 90–95% of patients harboring KRAS mutations. Nevertheless, KRAS has long been considered one of the most notorious "undruggable targets" in cancer research.

The recent development of sotorasib and adagrasib, which selectively target the KRAS G12C mutation, ushered in the era of KRAS-targeted therapy. However, these agents have inherent limitations, as they act only against a specific mutation and bind exclusively to the inactive RAS-OFF conformation.

Daraxonrasib adopts a fundamentally different strategy. Rather than targeting a single KRAS mutation, it is designed to directly inhibit the active, signaling form of RAS (RAS-ON). In other words, instead of focusing on a particular KRAS mutation, it blocks the RAS signaling pathway that cancer cells actively depend on for growth and survival.

Mechanistically, Daraxonrasib binds to activated RAS proteins through a cyclophilin A-mediated mechanism, enabling activity across multiple KRAS variants. Consequently, it has the potential to inhibit tumors harboring KRAS G12D, G12V, and G12R mutations, as well as malignancies driven by NRAS or HRAS alterations.

Even more intriguing is its potential efficacy in certain tumors that lack KRAS mutations. Although these tumors are KRAS wild-type, persistent activation of the RAS signaling pathway may still occur through mechanisms such as EGFR, HER2, or FGFR activation, or NF1 loss. Many of these tumors remain dependent on RAS signaling for growth and survival. By targeting activated RAS itself, Daraxonrasib has the potential to extend its therapeutic benefit beyond specific KRAS mutations to a broader spectrum of RAS-dependent cancers.

Doubling Overall Survival Compared with Standard Therapy

RASolute 302 was a global Phase III clinical trial involving 500 patients with metastatic pancreatic cancer who had previously received one or more prior lines of systemic therapy. Approximately 92% of enrolled patients harbored KRAS G12 mutations, while the remaining participants had KRAS G13, Q61 mutations, or KRAS wild-type tumors.

The study results were among the most highly anticipated late-breaking clinical trial presentations at ASCO 2026.

Table 1. Key Results of the RASolute 302 Clinical Trial

A Remarkable Survival Benefit Rarely Seen in Pancreatic Cancer

Most notably, the 60% reduction in the risk of death (HR 0.40) represents a magnitude of survival benefit that has rarely been observed in the history of pancreatic cancer treatment. Even when compared with randomized clinical trials reported over the past several decades, the results stand out as an exceptionally impressive achievement.

Evidence of Clinical Activity in KRAS Wild-Type Disease

The significance of the RASolute 302 trial extends beyond its impressive efficacy in KRAS-mutant pancreatic cancer. A key reason the study has attracted considerable attention is that it also included patients with KRAS wild-type tumors—a population that has received little attention during the development of previous KRAS-targeted therapies.

Approximately 90–95% of patients with pancreatic cancer harbor KRAS mutations, while the remaining 5–10% have KRAS wild-type tumors. Because currently available KRAS-targeted therapies directly inhibit specific KRAS mutations, patients without KRAS mutations have largely been excluded from targeted treatment strategies.

In RASolute 302, investigators conducted an exploratory subgroup analysis of patients with KRAS wild-type tumors and those harboring RAS G13/Q61 mutations, separate from the KRAS G12-mutant cohort. Although this subgroup consisted of only 42 patients (8.4% of the study population), the findings were particularly intriguing. Despite the small sample size and the exploratory nature of the analysis, a treatment effect in the same favorable direction as that observed in the KRAS G12-mutant cohort was also seen among patients with KRAS wild-type and non-G12 RAS-mutant tumors.

Although the analysis was exploratory and the number of patients was limited, the findings are nevertheless significant because they represent the first clinical signal suggesting that RAS pathway inhibition may also be effective in patients with KRAS wild-type and non-G12 RAS-mutant tumors. Importantly, the study demonstrated more than the therapeutic potential of targeting KRAS G12 mutations. More fundamentally, it begins to provide clinical support for the concept of "RAS dependency"—the notion that tumor cells may depend more on activated RAS signaling than on a specific KRAS mutation itself.

A Paradigm Shift in Pancreatic Cancer Treatment

For more than two decades, cytotoxic chemotherapy has remained the cornerstone of treatment for metastatic pancreatic cancer. However, the results achieved with Daraxonrasib suggest that this long-standing treatment paradigm may be changing.

In the future, treatment decisions may extend beyond simply determining whether a patient harbors a KRAS mutation. Instead, assessing the extent to which a tumor depends on RAS signaling may become increasingly important. In other words, the starting point of therapy is shifting from selecting chemotherapy regimens to understanding the RAS biology underlying each patient's tumor.

Moving Beyond KRAS Mutations to Target RAS Dependency

The true significance of this study lies not merely in demonstrating efficacy among patients with KRAS mutations.

More importantly, it provides the first clinical evidence suggesting that the fundamental biology of pancreatic cancer may be driven not by KRAS mutations per se, but by dependence on the RAS signaling network. Pancreatic cancer has long been regarded as a "KRAS-mutant disease." However, from a broader biological perspective, pancreatic cancer may be more accurately characterized as a malignancy driven by dependency on the RAS signaling network, of which KRAS is only one component.

Unlike conventional KRAS inhibitors that target specific KRAS mutations, Daraxonrasib inhibits activated RAS itself. As a result, the therapeutic target expands from a single gene mutation to the broader RAS signaling network.

Conclusion

The RASolute 302 study, presented at ASCO 2026, represents more than the successful development of a new anticancer agent. Rather, it may mark the beginning of a paradigm shift in the treatment of pancreatic cancer.

Daraxonrasib not only demonstrated a clinically meaningful improvement in survival among patients with KRAS-mutant pancreatic cancer, but also showed exploratory evidence of clinical activity in patients with KRAS wild-type and non-G12 RAS-mutant tumors, suggesting that activated RAS signaling itself, rather than a specific KRAS mutation, may constitute the true therapeutic target.

Perhaps even more noteworthy is that, unlike previous precision oncology approaches targeting relatively small biomarker-defined populations such as EGFR, ALK, and HER2, Daraxonrasib demonstrated meaningful clinical benefit by targeting the RAS signaling axis, which includes the KRAS mutations present in approximately 90–95% of pancreatic cancers. In doing so, it provides the first compelling evidence for a targeted therapeutic strategy with the potential to benefit the vast majority of patients with pancreatic cancer, rather than only a limited molecularly defined subgroup.

Although further validation is warranted, Daraxonrasib appears poised to become the first representative of the pan-RAS-targeted therapy era, with the potential to fundamentally reshape the future of pancreatic cancer treatment.

Source: The Bio (https://www.thebionews.net)